NasdaqCM:ORGOBiotechs
Organogenesis Holdings (ORGO) After Earnings Cut, Guidance Reset And $75 Million Raise, Still A Bargain?
What the latest earnings mean for Organogenesis Holdings stock
Organogenesis Holdings (ORGO) is back in focus after second quarter results showed sharply lower revenue and a much wider net loss, alongside a deeper revenue outlook cut and a planned US$75 million equity raise.
The earnings update matters for you because it reshapes expectations on cash generation, dilution risk and how much flexibility Organogenesis Holdings might have to fund its wound care portfolio, including products like...